Emmett T. Cunningham
Vice ChairmanDr. Emmett T. Cunningham, Jr., M.D., Ph.D., M.P.H., is Chairman of Oryon Cell Therapies, Inc. He is Vice Chairman of the Board of NovaBridge Biosciences from February 2026. He is Co-Founder & Executive Chairman of Visara, Inc. He is Director of InflammX Therapeutics Inc. and Aviceda Therapeutics, Inc. Dr. Cunningham is Scientific Advisor of NexEos Diagnostics, Inc. Dr. Cunningham is Executive Chair of Eyconis, Inc. He serves as Member of Strategic Advisory Board at RevOpsis Therapeutics, Inc. from may 2024. He is Director at Nacuity Pharmaceuticals, Inc from April 2024. He is an ophthalmology industry veteran with experience as a full-time investor and entrepreneur who has led or co-led investments and partnerships in the medical device and biotechnology space that have supported the FDA approval of multiple therapeutics. He is also an internationally recognized specialist in infectious and inflammatory eye disease with over 400 publications. Prior to HealthQuest and Eyconis, Dr. Cunningham served as a Senior Managing Director at Blackstone, Inc. following that firm's acquisition of Clarus Ventures in 2018. At Clarus, Dr. Cunningham was a member of the full-time investment team since the firm's inception in 2006. From 2001 to 2005, Dr. Cunningham was the Senior Vice President of Medical Strategy at Eyetech Pharmaceuticals, Inc He serves as a Senior Partner at HealthQuest Capital since joining in 2023. He is Co-Founder & Executive Chairman of Eyconis, Inc. He served as Operating Partner of Blackstone Life Sciences - San Francisco at Blackstone Inc. since January 2022 until March 2023. He served as Director at SFJ Pharmaceuticals, Inc. from June 2014 to March 2023. Dr. Cunningham served as Scientific & Clinical Advisors at Aura Biosciences, Inc. since December 2018. He serves as Managing Director at Clarus Ventures LLC from January 2017 to November 2018 and at Clarus IV, L.P. Dr. Cunningham joined Clarus Ventures/Clarus Funds in 2006 as a Principal and previously served as a Partner. Dr. Cunningham served as Director of Galera Therapeutics, Inc. since September 2018. He had been Senior Managing Director of the Blackstone Life Sciences - San Francisco at Blackstone Inc. since December 2018. Dr. Cunningham serves as an Advisor of Ophthalmology at Circadian Technologies Limited. He is the Co-Founder and Chairman of the Ophthalmology Innovation Summit since October 2009. Dr. Cunningham served as an Adjunct Clinical Professor of Ophthalmology at Stanford University School of Medicine since July 2008 and a Research Associate at The Francis I. Proctor Foundation, UCSF School of Medicine. He serves as Director of the Uveitis Service at California Pacific Medical Center at NYU from 2002 to 2005. Dr. Cunningham has accumulated wide experience in the biomedical and biopharmaceutical sectors. Prof. Dr. Cunningham was a Partner at SARcode Bioscience, Inc. He was a Clinical Professor of Ophthalmology at NYU Elaine A. and Kenneth G. Langone Medical Center. He was Clinical Professor at NYU from 2002 to 2005. Dr. Cunningham served as a Clinical Professor of Ophthalmology at New York University School of Medicine from 2002 to 2005, where he held a tenured position at the University of California-San Francisco. He served as Senior Vice President of Medical Strategy at Eyetech Pharmaceuticals, Inc. (alternate name: Oldtech, Inc.) from February 2004 to December 2005 and prior to that, as Vice President of Clinical Research Development and Licensing from April 2002 to February 2004. At Eyetech, Dr. Cunningham helped build, played a leadership role in the development and approval and lead the team that developed and commercialized Macugen for age-related macular degeneration, where he helped build and lead the team that developed and commercialized Macugen. Prior to Eyetech, Dr. Cunningham served as Early Clinical Leader at Pfizer, Inc., where he was responsible for the clinical development of early phase central nervous system compounds and the in-licensing of early and late-stage therapeutic candidates in ophthalmology from August 2001 to April 2002. Dr. Cunningham was responsible for the clinical development of early phase central nervous system compounds and the in-licensing of early and late-stage therapeutic candidates in ophthalmology. He was a Director of Graybug Vision, Inc. since April 2016 until September 25, 2020. He served as a Director of Restoration Robotics, Inc. from August 2011 to June 13, 2018. He serves as a Director of ViewPoint Therapeutics, Inc. He was Independent Director of Lumos Pharma, Inc since January 2019 till February 16, 2021. He has been a Director of Lumo Pharma Inc, since March 18, 2020. Dr. Cunningham has been a Director of Graybug Vision, Inc. since May 2, 2016. He serves on Scientific Advisory Board of Aerie Pharmaceuticals, Inc. He serves as a Director of Avillion since December 2014. He served as Independent Director at Annexon, Inc. (Annexon Biosciences) since December 2014 until February 25, 2021 and served as a Director of Silktech Biopharmaceuticals from November 2017 to March 2023. Dr. Cunningham serves as a Board Observer of Avillion and Tisbury Pharmaceuticals, Inc. He serves as a Member of the Scientific Advisory Board of Comentis Inc. He served as a Director of FerroKin BioSciences, Inc. and Pearl Therapeutics Inc. He served as a Board Observer of Ophthotech Corp. and Aerie Pharmaceuticals. Dr. Cunningham served as Board Observer of FerroKin BioSciences, Inc., Taligen Therapeutics Inc., Zogenix, Inc. and Pearl Therapeutics Inc. He served as a Director for SARcode Inc. and Neomend, Inc. He served as a Director of SARcode Bioscience, Inc. Dr. Cunningham served as a Member of the Scientific Advisory Boards of ESBAtech AG since February 2009. He served as a Director of both the Uveitis Service and Kimura Ocular Immunology Laboratory at the University of California at San Francisco (UCSF) from 1995 to 2001. Dr. Cunningham is an internationally recognized specialist in infectious and inflammatory eye disease with over 300 publications and six textbooks. He has a fellowship in public health ophthalmology at the Wilmer Eye Institute in Baltimore. He completed both a residency in ophthalmology and fellowship training in Corneal Disease and Uveitis at UCSF and The Francis I. Proctor Foundation, a medical retina and uveitis fellowship at Moorfields Eye Hospital. Dr. Cunningham holds a B.s. from Drexel University, a M.D. and a M.P.H. in epidemiology and statistics from Johns Hopkins University and holds B.A. in public health from Johns Hopkins University and a Ph.D. in Neuroscience from the University of California at San Diego (UCSD) at The Salk Institute.
Positions
- Company NameNovaBridge BiosciencesStock CodeNBPPositionVice Chairman
